Skip to content

Actelion gets go-ahead in Europe for hypertension med despite deaths

April 7, 2017

The European Medicines Agency on Friday gave its green light for doctors to continue using Actelion’s Uptravi, saying a review after five patient deaths in France did not suggest an increase in mortality linked to the pulmonary arterial hypertension drug.

“No changes to the prescribing information are considered necessary,” said the agency, which initiated its review after France’s drug regulator in January issued a “Dear Doctor” letter recommending doctors not begin new Uptravi treatments pending an investigation.

Johnson & Johnson is in the midst of a $30 billion takeover of Actelion, which said this month the deal is on track to close in the second quarter.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: